Pearls and pitfalls in nonalcoholic fatty liver disease: tricky results are common

Abstract

Interpretation of diagnostic and surveillance laboratory results and imaging in liver disease is fraught with misinterpretation and/or uncertainty. Nonalcoholic fatty liver disease (NAFLD) represents an ever-growing proportion of liver disease cases but presents unique challenges for the clinician. Given the necessity of excluding other etiologies of liver disease, NAFLD can at times represent a challenging diagnosis as non-invasive assessment and biopsy are imperfect tests with important limitations. Similarly, cautious review of laboratory reports is necessary to avoid missing abnormal pathophysiology. The presence of lab values within the standard reference range may be concerning in the setting of chronic liver disease (“abnormally normal”) and conversely results flagged as abnormal may not necessarily be of great concern (“normally abnormal”). This review provides a framework for the clinician to review common diagnostic challenges in NAFLD and enhance patient care.

Keywords

Nonalcoholic fatty liver disease / fibrosis / cryptogenic cirrhosis / sarcopenia / autoantibodies

References

[1] YounossiZM,AbdelatifD,HenryL.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[2] ScaglioneS,CaoG.The epidemiology of cirrhosis in the United States: A Population-based Study.J Clin Gastroenterol2015;49:690-6

[3] PaisR,CalmusY.NAFLD and liver transplantation: Current burden and expected challenges.J Hepatol2016;65:1245-57 PMCID:PMC5326676

[4] FrancqueSM,KwantenWJ.Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications.J Hepatol2016;65:425-43

[5] RatziuV,HeurtierA.LIDO Study GroupSampling variability of liver biopsy in nonalcoholic fatty liver disease.Gastroenterology2005;128:1898-906

[6] OzturkA,GeeMS.Quantitative hepatic fat quantification in non-alcoholic fatty liver disease using ultrasound-based techniques: a review of literature and their diagnostic performance.Ultrasound Med Biol2018;44:2461-75 PMCID:PMC6628698

[7] HagströmH,EkstedtM.Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.J Hepatol2017;67:1265-73

[8] BallestriS,BaldelliE.Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease.Diagnostics (Basel)2021;11:98 PMCID:PMC7827076

[9] McPhersonS,HendersonE,DayCP.Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.Gut2010;59:1265-9

[10] McPhersonS,DufourJF.Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis.Am J Gastroenterol2017;112:740-51 PMCID:PMC5418560

[11] DoychevaI,AllendeD,WattKD.Low utility of noninvasive fibrosis scores in young adults with nonalcoholic fatty liver disease.Am J Gastroenterol2017;112:652-3

[12] CasteraL.Non-invasive tests for liver fibrosis in NAFLD: creating pathways between primary healthcare and liver clinics.Liver Int2020;40 Suppl 1:77-81

[13] TapperEB,NasserI,LaiM.The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease.Am J Gastroenterol2016;111:677-84 PMCID:PMC4860094

[14] ChangPE,NguJH,TanCK.Clinical applications, limitations and future role of transient elastography in the management of liver disease.World J Gastrointest Pharmacol Ther2016;7:91-106 PMCID:PMC4734958

[15] EddowesPJ,AllisonM.Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.Gastroenterology2019;156:1717-30

[16] ŞirliR,DeleanuA.Comparison between the M and XL probes for liver fibrosis assessment by transient elastography.Med Ultrason2014;16:119-22

[17] LoombaR.Advances in non-invasive assessment of hepatic fibrosis.Gut2020;69:1343-52 PMCID:PMC7945956

[18] NewsomePN,DeeksJJ.FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.Lancet Gastroenterol Hepatol2020;5:362-73 PMCID:PMC7066580

[19] ChalasaniN,LavineJE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.Hepatology2018;67:328-57

[20] YeQ,YeoYH.Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:739-52

[21] AmpueroJ,Gallego-DuránR.HEPAmet RegistryThe effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.Aliment Pharmacol Ther2018;48:1260-70

[22] GunnNT.The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom.Clin Liver Dis2018;22:109-19

[23] JemalA,CenterMM,WardE.Global cancer statistics.CA Cancer J Clin2011;61:69-90

[24] StineJG,ZimmetA.Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases.Aliment Pharmacol Ther2018;48:696-703 PMCID:PMC7495494

[25] MarreroJA,SirlinCB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology2018;68:723-50

[26] SimmonsO,YokooT.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis.Aliment Pharmacol Ther2017;45:169-77 PMCID:PMC7207219

[27] BestJ,SowaJP.GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol2020;18:728-35.e4

[28] CaldwellSH,IezzoniJC,BattleEH.Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease.Hepatology1999;29:664-9

[29] ThuluvathPJ,ThuluvathAJ.Is cryptogenic cirrhosis different from NASH cirrhosis?.J Hepatol2018;68:519-25

[30] CaldwellS.Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name.J Hepatol2018;68:391-2

[31] ElAtrache MM,DivineG.Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome.Clin Transplant2012;26:E505-12

[32] HenryZH.How to identify the patient with nonalcoholic steatohepatitis who will progress to cirrhosis.Gastroenterol Clin North Am2020;49:45-62

[33] MofradP,HaqueM.Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.Hepatology2003;37:1286-92

[34] PratiD,ZanellaA.Updated definitions of healthy ranges for serum alanine aminotransferase levels.Ann Intern Med2002;137:1-10

[35] RuhlCE.Upper limits of normal for alanine aminotransferase activity in the United States population.Hepatology2012;55:447-54 PMCID:PMC3268908

[36] KasaralaG.Standard liver tests.Clin Liver Dis (Hoboken)2016;8:13-8 PMCID:PMC6490189

[37] VermaS,HartJ.Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).Liver Int2013;33:1398-405

[38] ShermanDS,TeitelbaumI.Assessing renal function in cirrhotic patients: problems and pitfalls.Am J Kidney Dis2003;41:269-78

[39] FrancozC.Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter.J Hepatol2019;70:828-30

[40] YooJJ,KimYS.Estimation of renal function in patients with liver cirrhosis: Impact of muscle mass and sex.J Hepatol2019;70:847-54

[41] HongHC,ChoiHY.Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study.Hepatology2014;59:1772-8

[42] LeeYH,KimSU.Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011).J Hepatol2015;63:486-93

[43] KooBK,JooSK.Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.J Hepatol2017;66:123-31

[44] FormicaRN,BoyleG.Simultaneous liver-kidney allocation policy: a proposal to optimize appropriate utilization of scarce resources.Am J Transplant2016;16:758-66

[45] NadelsonJ,NairS.Glycated hemoglobin levels in patients with decompensated cirrhosis.Int J Endocrinol2016;2016:8390210 PMCID:PMC5110874

[46] UtzschneiderKM.Review: The role of insulin resistance in nonalcoholic fatty liver disease.J Clin Endocrinol Metab2006;91:4753-61

[47] EnglishE,SmithG,KilpatrickES.The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review.Diabetologia2015;58:1409-21

[48] TzartzevaK,RichNE.Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis.Gastroenterology2018;154:1706-18.e1 PMCID:PMC5927818

[49] TayobN,DoKA.Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm.Clin Gastroenterol Hepatol2016;14:469-475.e2 PMCID:PMC4744807

[50] Olivares-GazcaJC,Mendez-HuertaMA,Orea-MartinezJG.More on the thrombocytopenia of the non-alcoholic fatty liver disease.Hematology2017;22:316-9

[51] López-TrujilloMA,Cantero-FortizY.Nonalcoholic fatty liver disease and thrombocytopenia III: its association with insulin resistance.Clin Appl Thromb Hemost2019;25:1076029619888694 PMCID:PMC7019400

[52] PankeCL,Villela-NogueiraCA.Evaluation of thrombocytopenia in patients with non-alcoholic fatty liver disease without cirrhosis.Ann Hepatol2020;19:88-91

[53] YonedaM,SumidaY.Japan Study Group of Nonalcoholic Fatty Liver DiseasePlatelet count for predicting fibrosis in nonalcoholic fatty liver disease.J Gastroenterol2011;46:1300-6

[54] HabibA,AbouassiS.High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics.Clin Gastroenterol Hepatol2005;3:286-91

[55] ArguelloG,ArreseM.Recent insights on the role of cholesterol in non-alcoholic fatty liver disease.Biochim Biophys Acta2015;1852:1765-78

[56] ByrneCD.NAFLD: a multisystem disease.J Hepatol2015;62:S47-64

[57] KontushA.HDL-mediated mechanisms of protection in cardiovascular disease.Cardiovasc Res2014;103:341-9

[58] FlorénCH,FranzénJ.Lecithin: cholesterol acyltransferase in liver disease.Scand J Clin Lab Invest1987;47:613-7

[59] ChangL,BarterP.High density lipoprotein subpopulations in chronic liver disease.Hepatology1986;6:46-9

[60] TrifanA,StanciuC.Update on adrenal insufficiency in patients with liver cirrhosis.World J Gastroenterol2013;19:445-56 PMCID:PMC3558568

[61] JangJY,SohnJH.Relative adrenal insufficiency in chronic liver disease: its prevalence and effects on long-term mortality.Aliment Pharmacol Ther2014;40:819-26

[62] PianoS,TononM.Including relative adrenal insufficiency in definition and classification of acute-on-chronic liver failure.Clin Gastroenterol Hepatol2020;18:1188-96.e3

[63] AdamsLA,AnguloP.The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease.Am J Gastroenterol2004;99:1316-20

[64] LoriaP,LeonardiF.Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.Dig Dis Sci2003;48:2173-81

[65] VuppalanchiR,WilsonLA.Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.Hepatol Int2012;6:379-85 PMCID:PMC3511661

[66] ZhouYJ,MaHL.Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD.Nutr Metab Cardiovasc Dis2021;31:552-60

[67] KonijnAM.5 Iron metabolism in inflammation.Baillieres Clin Haematol1994;7:829-49

[68] JehnM,GuallarE.Serum ferritin and risk of the metabolic syndrome in U.S. adults.Diabetes Care2004;27:2422-8

[69] KowdleyKV,WilsonLA.NASH Clinical Research NetworkSerum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.Hepatology2012;55:77-85 PMCID:PMC3245347

[70] LicataA,CabibboG.Hyperferritinemia is a risk factor for steatosis in chronic liver disease.World J Gastroenterol2009;15:2132-8 PMCID:PMC2678584

[71] RuddellRG,BarwoodJM.Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells.Hepatology2009;49:887-900 PMCID:PMC2701483

[72] WalkerNM,RyanRJ.Serum ferritin concentration predicts mortality in patients awaiting liver transplantation.Hepatology2010;51:1683-91

[73] KowdleyKV,AhnJ.ACG Clinical Guideline: hereditary hemochromatosis.Am J Gastroenterol2019;114:1202-18

[74] Gonzalez-CasasR,Moreno-OteroR.Spectrum of anemia associated with chronic liver disease.World J Gastroenterol2009;15:4653-8 PMCID:PMC2754513

[75] VassiliadisT,VakalopoulouS.Spur cells and spur cell anemia in hospitalized patients with advanced liver disease: incidence and correlation with disease severity and survival.Hepatol Res2010;40:161-70

[76] AndrèsE,ZhuJ.The pathophysiology of elevated vitamin B12 in clinical practice.QJM2013;106:505-15

[77] ArendtJF.Unexpected high plasma cobalamin : proposal for a diagnostic strategy.Clin Chem Lab Med2013;51:489-96

[78] WentworthB.Revisiting vitamin B12 deficiency: A Clinician’s Guide For the 21st Century.Practical Gastroenterology2018;XLII:28-49

[79] HuntA,RobinsonS.Vitamin B12 deficiency.BMJ2014;349:g5226

[80] TeufelA,KahalyGJ.Concurrent autoimmune diseases in patients with autoimmune hepatitis.J Clin Gastroenterol2010;44:208-13

[81] NiafarM,PorhomayonJ.The role of metformin on vitamin B12 deficiency: a meta-analysis review.Intern Emerg Med2015;10:93-102